CURRICULUM VITAE
Name:Nathalie Scholler(née Buonavista), M.D., Ph.D.
Present Position:Tenure-track Assistant Professor, Department of Obstetrics and Gynecology.
Office:University of Pennsylvania School of Medicine.
Center for Research on Reproduction and Women's Health
Biomedical Research Building II/III, Room 1309
421 Curie Blvd., Philadelphia, PA, 19104-6160
Phone: (215) 898 0164 – Fax: (215) 573 5129 -
Place of Birth:Marseille, France
Education:
1995PhD, Immunology University of Science of Aix-Marseille II, France
1990Diplômed’étudesapprofondies (equiv. MS)University of Science of Aix-Marseille II, France.
Immunology
1988MD, General MedicineSchool of Medicine, Marseille, France.
Training:
1995-1997Post-Doctoral FellowshipAutoimmunity Department, Bristol Myers SquibbPharmaceutical Institute, Seattle, WA
1991-1995Scientific FellowshipCentre d’Immunologie de Marseille-Luminy,
Universityof Aix-Marseille II, France.
1986-1988Intern in General Medicine University of Aix-Marseille Affiliated Hospitals, Marseille, France.
Additional Training:
1993Human genome analysis: from YAC to geneThe 11th Welcome Summer School. United
Medical and Dental Schools of Guy’s and St Thomas’s Hospitals, London, UK
2004Engineering of Recombinant AntibodiesCambridge Healthtech Institute, Needham, MA
Faculty Appointments and Professional Positions:
Nov. 2007-presentTenure-track Assistant ProfessorDepartment of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA
2003-2007Senior Staff Scientist Laboratory DirectorTranslational and Outcomes Research laboratory, Molecular Diagnostics Program, Fred HutchinsonCancer Research Center, Seattle, WA.
2001-2003Senior Research ScientistDepartment of Biochemistry, Seattle Genetics,Inc.Bothell, WA.
1997-2001Staff Research ScientistDepartment of Tumor Immunology, Pacific Northwest Research Institute, Seattle, WA.
1990-1995 Physician- Sports MedicineFrench National Federation of Judo, Marseille, Fr.
1989-1990PhysicianScientistFrench National Institute of Health and Medical
Research (INSERM), France and Brazil.
1988-1989Resident in Internal Medicine Hôpital St Joseph, Marseille, France.
Academic and Institutional committees
2010-presentPenn Institute for Immunology (Penn IFI), UPenn Member
2010-presentBioengineering Graduate Studies, Bioengineering Graduate Group, UPenn Member
2009-presentBiomedical Graduate Studies, Immunology Graduate Group, UPenn Member
2008-present FOCUS Advisory Committee, UPenn Member
2008-present Immunobiology program, Tumor Immunology Interest GroupFull Research Member
Abramson Cancer Center, UPenn
2007-present Penn Ovarian Cancer Research Center (Penn OCRC), UPenn Member
Memberships:
2010-presentNew York Academy of Sciences (NYAS)
2010-presentAmerican Association for Cancer Research (AACR)
2008-present Consortium for Functional Glycomics(CFG)
2008-present Institute for Translational Medicine and Therapeutics (ITMAT)
2001-presentAmerican Association of Immunologists (AAI)
2001-presentAmerican Association for the Advancement of Science (AAAS)
2001-presentAmerican Society of Gene and Cell Therapy(ASGCT)
Scholarships, Fellowships and Awards:
2011Junior Faculty Travel AwardAmerican Association of Immunologists (AAI 2011)
San Francisco, CA.
2003-2004Career Development Award Marsha Rivkin Center for Ovarian Cancer Research
(MRCOCR), Seattle, WA.
2001-2003Marsha Rivkin Center Scholar Award MRCOCR, Seattle, WA
1995PrivatefellowshipLa Fondation pour la Recherche Médicale, France.
1991-1994National scholarship French Ministry of Research & Technology, France.
1990PrivatefellowshipLa Fondation pour la Recherche Médicale, France.
1980-1986RegionalscholarshipProvince des Bouches-du-Rhône, France.
Organizing roles
2011HostBreak-out discussion at the 13th Annual Phage and Yeast Display of Antibodies & Proteins conference, Protein Engineering Summit (PEGS) - May 9-10 - Boston, MA.
2010ModeratorCenter for Research on Reproduction and Women’s Health Annual Research Retreat and the Cuozzo lecture- May 19- University of Pennsylvania, PA.
2010Block Chair 97th AAI Annual meeting, Tumor Immune Response session - May 7-10- Baltimore, MD
2009Block Chair 96th AAI Annual meeting,Tumor Immune Escape - May 8-12- Seattle, WA
2008Block Chair 2nd International Conference on Ovarian Cancer: State of the Art and Future Directions -June 26 - July 1- Rhodes, Greece
Scientific Review, Consulting and Advisory roles:
2011Scientific reviewer for DOD Study section: Ovarian Cancer Research Program, Detection-Diagnosis and Clinical and Experimental Therapeutic, DD-CET
2011Scientific expert for Wolf, Greenfield & Sacks, P.C., Boston, MA.
2011Scientific reviewer for Kentucky Science & Engineering Foundation.
2010Consultant for Reckner Healthcare.
2010Advisory Board Member in the Editorial Board of Recent Patents on Biomarkers.
2010Advisory Board member for the 2nd Annual Cancer Targets and Therapeutics Conference, Oct. 20-22, San Francisco.
2010Scientific reviewer for the Health Research Council (HRC), New Zealand.
2010Scientific reviewer for DOD Study section: Ovarian Cancer Clinical and Experimental Therapeutics.
2009-2011Advisory Boardtenured Member in the Editorial board of Journal of Proteome Research.
2009Scientific reviewer for NIH Challenge grants in Health and Science Research (RC1).
2009Scientific reviewer for The Health Research Board, Ireland.
2008Scientific reviewer for Maryland Industrial Partnerships (MIPS).
2008Scientific reviewer for DOD Study section: Ovarian Cancer Research Program.
2008 Consultant for Ernst & Young Life and Health Science Advisory, Paris, France.
Editorial Positions
2011-presentPeer-ReviewerDisease markers.
2011-presentPeer-ReviewerOMICS: A Journal of Integrative Biology
2011-presentPeer-ReviewerNature Communications.
2011-presentPeer-ReviewerBiomarkers in Medicine
2011-presentPeer-ReviewerMolecular Pharmaceutics.
2011-presentPeer-ReviewerJournal of Controlled Release.
2010-presentPeer-ReviewerCancer Immunology Immunotherapy.
2010-presentAssociate Editorial Board memberJournal of Translational Research
2010-presentPeer-ReviewerJournal of Proteomics
2009-present Peer-ReviewerGynecologic Oncology
2009-present Peer-ReviewerPlosONE
2009-present Peer-ReviewerClinical Science
2009-present Peer-ReviewerCancer Epidemiology
2009-present Author-in-Chief Encyclopedia of Cancer, 2nd edition
2006-present Peer-ReviewerCancer Letters
2008-present Peer-ReviewerCancer Biology & Therapy
2008-present Peer-ReviewerGynecologic and Obstetric Investigation
2008-present Peer-ReviewerMolecular and Cellular Proteomics
Presentations
2011 Poster presentation “Development of T-bodies expressing CIR directed against Endosialin/TEM1 for immune-gene therapy against breast cancer”. Nathalie Scholler, Stephen P. Santoro, Shree Joshi, Aizhi Zhao, and George Coukos, Era of Hope 2011, August 2-5, Orlando, FL.
2011Invited speaker“Paired yeast-display/secretory vectors for rapid isolation of site-specific biotinylated affinity reagents”, 13th Annual Phage and Yeast Display of Antibodies & Proteins conference, Protein Engineering Summit (PEGS) - May 9-10 - Boston, MA.
2011Oral presentation“Tumor released mesothelin contributes to the polarization of tumor-infiltrating macrophages”,14th Annual Meeting of theTranslational Research Cancer Centers Consortiumconference, Seven Springs Mountain Resort - Feb 24-26 - Seven Springs, PA
2011Invited speaker“GPI anchors: much more than an alternative strategy for cell surface presentation”GTCbio’s 3rd Oncology Biomarker Conference, Jan 27-28, San Diego, CA.
2011Poster presentation“Tumor-infiltrating B-cells express toll-like receptors and exert proangiogenic activity in ovarian cancer”. S. Nunez-Cruz, W. Quinn, D. Connolly, P. Gimotty, and N. Scholler. EMBO 2011 meeting. ImmunologyMetabolism- Centre d’Immunologie de Marseille-Luminy, January 13-14, Marseille, France.
2010Invited speaker “Role of B cells in cancer development”. 23rd Annual Immunology Retreat. November 5-7. Lancaster, PA
2010Invited speaker “Novel mechanism for M2 polarization of tumor-infiltrating macrophages via GPI-anchored proteins”. Marsha Rivkin Center Ovarian Cancer Research Symposium, session: On the Horizon: Developing Therapeutics. Oct 28-29, Seattle, WA.
2010Invited speaker“Tumor-infiltrating lymphocytes B (TIL-B) angiogenic properties contribute to tumor growth in presence of complement”. Department of Immunopathology, NIAID/NIH. June 3, Rockville, MD.
2010Invited speaker“Study of the role of tumor-infiltrating B-cells in a transgenic mouse model of ovarian cancer”. Tumor Immunology Interest Group. May 20, University of Pennsylvania, PA.
2010Poster presentation"Mannose receptor binding triggers M2-macrophage polarization" Denarda Dangaj, Selene Nunez-Cruz, Aizhi Zhao and Nathalie Scholler. Canary Foundation Early Detection Symposium, May 25-27, Stanford, CA
2009Invited speaker“Alkali-resistant, site-specific biotinylated, high affinity reagent for IgG capture”. Bio-Rad laboratories, Dec. 9, Hercules, CA.
2009Invited speaker“Tumor-infiltrating B lymphocytes in ovarian cancer”. FCCC-UPENN Quarterly Ovarian Cancer Research meeting.Fox Chase Cancer Research Center, Dec. 3, Philadelphia PA.
Presentations (continue)
2009 Invited speaker “Study of the role of CA125 and adipocytes in the alternative complement pathway during ovarian cancer physiopathology” and “Blocking of CA125/Mesothelin-dependent peritoneal metastasis with antibodies and biobodies”. Fred Hutchinson Cancer Research Center, Scientific Program Committee Meeting.Nov 16, Seattle WA.
2009 Poster presentation "Blocking tumor/macrophages cross-talk with anti-mannose receptor recombinant antibodies to trigger tumor rejection" Denarda Dangaj, Aizhi Zhao, Raphael Sandaltzopoulos, George Coukos and Nathalie Scholler. 2009 NCI Translational Science Meeting (TSM 2), session: Therapeutic Antibodies and Combination Therapies, November 5-7, Vienna, VA.
2009 Poster presentation“Characterization of Tumor Infiltrating-B cells (TIL-B) in a transgenic mouse model of serous ovarian cancer.” Nunez-Cruz, S., Guerra, M., Queen, W., Scott P., Connolly, D., Cancro, M.P., Gimotty, P., and Scholler, N. Frontiers in Basic Immunology, NIH, October 1-2, Bethesda, MD.
2009Invited speaker “Rapid identification of high affinity reagents using a yeast-expressed recombinant antibody
platform”, Dana Farber/Harvard Medical School, June 19, Boston, MA.
2009Invited speaker “Systèmes d’expression d’anticorps recombinants dans la levure: Application en
Immunociblage”. INSERM -U 928- TAGC & UMR 928 Université de la Méditerranée, June 10, Marseille-Luminy, France.
2009Invited speaker “Scouting glycoproteins in ovarian cancer”. CRRWH annual retreat, University of Pennsylvania, May 27, Philadelphia, PA.
2009Invited speaker “Yeast-expressed recombinant antibody platform for rapid identification of high affinity reagents”. Institute of System Biology, May 11, Seattle, WA
2009Invited speaker “Role of tumor-released GPI-anchor proteins in macrophage polarization”. Centocor, University of Pennsylvania, March 16, Philadelphia, PA
2009Invited speaker “Biobody technology.” Drexel Institute for Biotechnology and Virology ResearchatPennsylvania Biotechnology Center of Bucks County, March 11, Doylestown, PA.
2009Invited speaker“Yeast-expressed recombinant antibody (scFv) for discovery of cancer biomarkers”, GlaxoSmithKline, March 10, King of Prussia, PA
2009Invited speaker “Prevention of ovarian cancer peritoneal metastasis by designing blocking strategies of CA125/mesothelin interaction using natural or recombinant antibodies.”6th Cancer Drugs R&D Conference.February 19-20, Philadelphia, PA.
2009Invited speaker “The coming of age of ovarian cancer biomarkers.”2ndOncology Biomarkers Conference.Jan. 19-20, Miami, FL.
2008Invited speaker “Using yeast for display and secretion of recombinant antibodies”, LifeSensors, Inc. October 28, Malvern, PA.
2008 Invited speaker “Selection of high affinity anti-TEM1 scFv by magnetic and flow sortings of a novel yeast-display scFv library”, Bracco Research USA Inc, September 25, Princeton, NJ.
2008Invited speaker “Yeast-display scFv and biobodies”, Morphotek, Inc., July 14, Exton, PA.
2008Invited speaker “Generation of libraries of recombinant llama heavy-chain for diagnostic and discovery of cancer markers”.Second International Conference on Ovarian Cancer: State of the Art and Future Directions,June 26 - July 1, Rhodes, Greece
2008Poster presentation “Generation of recombinantlibraries of heavy-chain V regions derived from Llama Glama”. Scholler N., Gross J.A. and Urban N. Canary Foundation Early Detection Symposium, May 21-22, Stanford, CA.
2007Oral presentation “Development and in vitro Validation of anti-Mesothelin Biobodies that prevent CA125/Mesothelin-dependent Cell Attachment.”.Bergan L, Gross JA, Nevin B, Urban N and Scholler N. 15th SPORE Investigators’ Workshop Concurrent Poster Discussion Session:New Technologies and Methodologies in Translational Research II, July 7-10, Baltimore, MA.
2007Poster presentation“Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.”Scholler N, Bergan L, Gross JA, Garvik B, Nevin B, and Urban N.Federation of Clinical Immunology Societies (FOCIS) annual meeting, June 7-11, San Diego, CA.
Presentations (continue)
2007 Poster presentation “Generation of a new type of yeast-secreted biotinylated recombinant antibodies directed against mesothelin and able to prevent CA125/mesothelin-dependent cell attachment.”. Scholler N, Garvik B, Bergan L, Nevin B, Gross JA, and Urban N. ASGT10th Annual Meeting, May 30 - June 3, Seattle, WA.
2007 Invited speaker “Design of new classes of recombinant antibodies and validation for use in cancer diagnostics and therapy.” University of Pennsylvania May 16, Philadelphia, PA.
2007 Poster presentation “Validation of in vivo-biotinylated yeast-secreted recombinant antibodies for use in diagnostic tests.” Scholler N, Lowe K, Bergan L, Kampani A, Gross JA, Garvik B and Urban N. - BioMarker World Congress 2007, May 15–17, Philadelphia, PA.
2006Invited speaker “Utilisation d'un test d'adhésion cellulaire basé sur l'interaction CA125/mésotheline pour tester in vitro de nouvelles voies d'approches thérapeutiques pour la prévention de micro-métastases péritonéales du cancer de l'ovaire.” Institut de Cancérologie et d'Immunologie de Marseille IFR 137 (Institute of Cancer and Immunology) INSERM UMR 599, November 15, Marseille, France.
2006Invited speaker “Method for generation of in vivo biotinylated recombinant antibodies by yeast mating.” Laboratoire Technologies Avancées pour le Génome et la Clinique TAGC (Laboratory of Advanced Technology for Genome and Clinic) ERM 0206, November 14, Marseille –Luminy, France.
2006Invited speaker “Generation of antigen-specific recombinant antibodies in the absence of purified and/or immunogenic antigens.” Seattle Biomedical Research Institute, November 6, Seattle, WA.
2006Invited speaker “Generation of New Tools for Early Detection of Ovarian Cancer.” Complex Carbohydrate Research Center, University of Athens.September 29, Athens, Georgia.
2006Oral presentation “Bead-Based ELISA Assays for Validation of Ovarian Cancer Early Detection Markers.”- Scholler N, Crawford M, Sato A, Drescher CW, O’Briant KC, Kiviat N, Anderson GL and Urban ND. Sixth Biennial Symposium sponsored by the MRCOCR, September 7-8, Seattle, WA.
2006Oral presentation “Development of a CA125-Mesothelin Cell Adhesion Assay as a Screening Tool for Biologics Discovery.”Scholler N, Garvik B, Hayden-Ledbetter M, KlineT and UrbanND. Fourteenth SPORE Investigators’ Workshop Concurrent Plenary session, July 16-19, Baltimore MA.
2006Poster presentation. “Biobodies: generation and validation.” Scholler, N. and Garvik, B.American Association of Immunologists, May 12–16,Boston, MA.
2005Oral Presentation “Sandwich test ELISA with scFv antibodies: an alternative to an all-time favorite”-Scholler N, Garvik B and Urban N. Symposium of the Era of Hope Department of Defense Breast Cancer Research,Philadelphia, PA.
2004Poster presentation“Generating New Tools for CD83 Functional Studies: Identification of an Anti-CD83 Recombinant Antibody that Binds to an HB15-Alternate Epitope”Hamel Y, Greenberg P and Scholler N. Twelfth International Congress of Immunology, Montreal, Canada.
2004Oral presentation “Isolation of ovarian carcinoma-specific native proteins for development of new biomarkers.”Scholler N, Lampe P and Urban N.Eleventh SPORE Investigators Workshop, Baltimore, MD.
2002Oral presentation “CD83 regulates the development of cellular immunity”.Scholler N, Hayden-Ledbetter M, Dahlin A, Hellström I, Hellström KE and Ledbetter JA.FASEB Immunology, New Orleans, LA.
2001Oral presentation “CD83 is a adhesion receptor that binds monocytes and activated CD8+T cells”Scholler N, Disis ML, Dahlin A, Pullman J, Hellström KE and Hellström I. Eleventh International Congress of Immunology, Stockholm, Sweden.
2001Oral presentation “HER2 DNA immunization with costimulatory molecules elicits functional anti-HER2 antibodies and CD4+ T cell tumor infiltration.”Scholler N, Ledbetter M., Hellström KE, Hellström I, Ledbetter JA - Eleventh International Congress of Immunology, Stockholm, Sweden.
Presentations (continue)
2001Oral presentation “HER2 DNA immunization with costimulatory molecules elicits functional anti-HER2 Antibodies.”.Scholler N, Disis ML, Dahlin A, Pullman J, Hellström KE and Hellström I - Fourth Annual Meeting of the ASGT, Seattle, WA. Abstract published in Molecular Therapy. 3(5): S69-70.
2001Poster presentation “HER2 DNA immunization with costimulatory molecules”.Scholler N, Disis ML, Dahlin A, Pullman J, Hellström KE and Hellström I.Ninth SPORE Investigators Workshop, Washington, DC.
2000Oral presentation “Antibodies to the HER2 protein can be elicited with DNA immunization.” Scholler N, Disis ML, Pullman J, Hellström KE and Hellström I - Third Biennial Ovarian Cancer Research Symposium, Seattle, WA.
1998Oral presentation “DNA immunization with a combination of Rat Neu antigen, CD86 and 4-1BB ligand results in the generation of HER-2/neu (HER2) antibodies in Neu transgenic (neuT) mice.” Scholler N, Shiota FM, Pullman J, Hellström KE, Hellström I and Disis ML.Seventh International Conference on Gene Therapy of Cancer, Coronado, CA.
1994Poster presentation “Mapping of CTLA4-CD28 genomic region by yeast artificial chromosomes (YAC).” Buonavista N, Balzano C, Pontarotti P, Le Paslier D and Goldstein P.- May 11-15, Workshop Genome mapping and sequencing, Cold Spring Harbor, NY.
1992 Invited speaker“Interest and advantage of YAC technology for genome mapping”- September 15, Workshop Pulse Field Electrophoresis, Pharmacia, France.
Abstracts
2011“Characterization of a TEM1 tumor-targeting antibody”. George Coukos, Aizhi Zhao, Chunsheng Li, Daniel Ricklin, Tamara Seedial, and Nathalie Scholler, Era of Hope 2011, Orlando, FL.
2011“Developing magnetic nanoparticles for targeted nucleic acid delivery and detection” Poster presentation.Prantner A.M., Chen J., Murray C.B., and Scholler N. ASGCT 2011, May7 17-21, Seattle, WA.
2011“B cells infiltrating ovarian cancer exhibit a regulatory-like phenotype.”Selene Nunez-Cruz, William J. Quinn III, Denise C. Connolly and Nathalie Scholler. Oral presentation, The Journal of Immunology, 2011 supplement, AAI 2011, May 13-17, San Francisco, CA. Travel Award, Selene Nunez-Cruz.
2011“Mannose receptor regulates macrophage polarization in the tumor microenvironment”Denarda Dangaj, Shree Joshi, Aizhi Zhao, Raphael Sandaltzopoulos and Nathalie Scholler. Poster presentation, The Journal of Immunology, 2011 supplement, AAI 2011, May 13-17, San Francisco, CA.
2011“Role of TLR engagement on TIL-B and clinical implications for ovarian cancer.”Selene Nunez-Cruz, Matthew Guerra, Denise Connolly, Phyllis Gimotty and Nathalie Scholler.Poster presentation, AACR 2011, April 2-5, Orlando, FL.
2011“Developing targeted superparamagnetic iron oxides for combination chemohyperthermia” Prantner A.M., Chen J., Murray C.B., and Scholler N. Poster presentation, Immunochemotherapy: Correcting Immune Escape in Cancer, March 10, Philadelphia, PA.
2011“Modeling the human tumor-microenvironment in CD34 transplanted NSG mice” Marc Walter, Selene Nunez-Cruz, Ananda Mookerjee, Chongyun Fang, Andrea Facciabene, George Coukos, Gwenn Danet-Desnoyers and Nathalie Scholler. Poster presentation, Immunochemotherapy: Correcting Immune Escape in Cancer, March 10, Philadelphia, PA.
2011“Reconstitution of the human ovarian tumor-microenvironment in CD34-transplanted NOD-Scid-IL2Rc null (NSG) mice.” Marc Walter, Ananda Mookerjee, Selene Nunez-Cruz, Chongyun Fang, Andrea Facciabene, Daniel J. Powell Jr., George Coukos, Nathalie Scholler, and Gwenn Danet-Desnoyers. Poster presentation, TRC3 2011, February 24-26, Seven Springs, PA
2011“Modulation of the tumor microenvironment by targeting the co-inhibitory B7H4 molecule”.Denarda Dangaj, Shree Joshi, Aizhi Zhao, Daniel J. Powell Jr., Raphael Sandaltzopoulos and Nathalie Scholler.Poster presentation, TRC3 2011, February 24-26, Seven Springs, PA
2010“Characterization of scFv78: an anti-TEM1 scFv” Aizhi Zhao, Chunsheng Li, Daniel Ricklin, Tamara Seedial, George Coukos, Nathalie Scholler. International Society for Biological Therapy of Cancer (iSBTc).Poster presentation,October 2 - 4, Washington, D.C.The Journal of Immunotherapy, in press.
2010“Targeting of superparamagnetic iron oxide nanoparticles for cancer therapy based on localized hyperthermia” Andrew M. Prantner, Jun Chen, Christopher B. Murray and Nathalie Scholler. 6th annual Symposium Center for Translational Medicine, oral and poster presentations, June 4, Jefferson Medical College, Philadelphia, PA
Abstracts (continue)
2010“The binding of mannose receptor by tumor-released GPI-anchor proteins controlstumor-associated macrophage phenotype”, Denarda Dangaj, Selene Nunez-Cruz, Aizhi Zhao, Raphael Sandaltzopoulosand Nathalie Scholler.Oral presentation, CRRWH annual retreat, University of Pennsylvania, PA.Presentationwinner, D. Dangaj.
2010“Gold nanorods conjugated to tumor-specific antibody for the targeting of ovarian cancer” Kolin C. Hribar, Gregory R. Wiedman, Andrew Prantner, ChaitanyaDivgi, and Nathalie Scholler. Senior Design project of undergraduate students in Bioengineering, poster presentation, April 20, University of Pennsylvania, School of Engineering, PA.